Bosnalijek products soon to be available in Central and North American markets

(Patria) - Bosnalijek, the largest pharmaceutical company in Bosnia and Herzegovina, after registering the products Alerix ® , Bronchobos ® and Mecobalamin, will soon begin exporting these products to the market of Costa Rica in Central America.
After the European, Asian and African continents, by entering the Central American market, Bosnalijek opens a new perspective for the development and strengthening of the position of one of the most successful pharmaceutical companies in the region.

In parallel with the above, the company is finalizing activities for the registration of additional products in this market, and it is particularly important to mention that in the coming months, approval from the FDA (Food and Drug Administration) of the United States of America is expected for the import of the Lysobact ® group of products, which will open a completely new perspective for Bosnalijek.

"We are intensively working with our partners to finalize all activities related to FDA approval for the import of the Lysobact ® brand group of products. This is a project we have been working on for a long time and diligently, and we are excited about the fact that our best-selling brand will soon be available in pharmacies across the United States. The pharmaceutical industry is one of the most strictly regulated industries in the world, and opening new markets is demanding. The entire process of market access is extremely complex and requires meeting the highest possible quality standards, but thanks to our focus, commitment, continuous investment, and the knowledge and expertise of our employees, we are one step away from achieving this great goal," stated Bosnalijek.

"Despite the difficulties Bosnalijek has been facing recently, primarily concerning the Russian-Ukrainian crisis, we believe that we have once again shown that we can cope with all adversities and achieve good results. Continuous business improvement has been and remains our primary goal in order to ensure stable jobs for our employees and the uninterrupted growth and development of the company. This is confirmed by the fact that, despite numerous problems we are facing, we are recording growth both in the domestic and all export markets, with a 27% growth in sales to distributors and over 63% growth in sales from distributors to pharmacies compared to last year.

All of the above indicates our stability and readiness to face all challenges that come our way."